Skip to content

The evaluation of the clinical efficacy of the moxibustion of different storage time in the treatment of severe primary knee osteoarthritis

The evaluation of the clinical efficacy of the moxibustion of different storage time in the treatment of severe primary knee osteoarthritis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012628
Enrollment
Unknown
Registered
2017-09-10
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Storage 1 years moxa:moxibustion
storage 3years moxa:moxibustion

Sponsors

Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
38 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) aged 38 to 70 years; (2) meet the diagnostic criteria of primary knee osteoarthritis; (3) drug (non-steroidal anti-inflammatory drugs, pain relievers, traditional Chinese medicine and Chinese patent medicine) for knee osteoarthritis elution after 7 days, WOMAC96 joint index scores between > 48 to 72 or less, the grading for moderate to severe knee osteoarthritis disease; (4) the Kellgren and Lawrecne osteoarthritis class for II or III radiology.

Exclusion criteria

Exclusion criteria: (1) non-primary knee osteoarthritis (such as secondary knee osteoarthritis; Inflammatory or other rheumatic diseases; Symptomatic hip arthritis or patella osteoarthritis in the same side of the target knee (2) the target knee injury in nearly a year (such as acute injury of knee joint meniscus, or acute knee ligament damage/around fracture, etc.) or a history of surgery, or severe joint deformities (varus or valgus 8 degree or higher); Or peripheral tumor, tuberculosis or idiopathic bone necrosis; (3) the target knee joint was injected with glucocorticoid in the joint cavity for nearly three months, or injection of sodium hyaluronate in the joint cavity within 2 weeks; (4) patients with acetaminophen, non-steroidal anti-inflammatory drugs or analgesics for other diseases; (5) uncontrolled hypertension or diabetes, severe cardiovascular and cerebrovascular, pulmonary, liver, spleen, kidney and hematopoietic system disease, tumor, hemorrhagic disease and mental illness; (6) scar or skin sensation; (7) pregnant or lactating women; (8) refusal to sign informed consent.

Design outcomes

Primary

MeasureTime frame
WOMAC osteoarthritis index pain project score;visual analogue scale, VAS;

Secondary

MeasureTime frame
WOMAC osteoarthritis index score, rigid project score and joint function project score;Overall assessment of patients;

Countries

China

Contacts

Public ContactHONG ZHAO

Institute of Acupuncture and Moxibustion China Academy of Chinese Medical Sciences

hongzhao2005@aliyun.com+86 13911132103

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026